Last reviewed · How we verify
Self-injectable epinephrine
Self-injectable epinephrine works by stimulating the body's natural response to anaphylaxis through the release of epinephrine.
Self-injectable epinephrine works by stimulating the body's natural response to anaphylaxis through the release of epinephrine. Used for Anaphylaxis treatment.
At a glance
| Generic name | Self-injectable epinephrine |
|---|---|
| Also known as | EpiPen |
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | Adrenergic agonist |
| Target | Adrenergic receptors |
| Modality | Small molecule |
| Therapeutic area | Allergy and Anaphylaxis |
| Phase | Phase 3 |
Mechanism of action
Epinephrine is a medication that mimics the body's natural response to anaphylaxis, causing blood vessels to constrict, heart rate to increase, and bronchial tubes to dilate. This helps to alleviate symptoms such as difficulty breathing, rapid heartbeat, and a drop in blood pressure.
Approved indications
- Anaphylaxis treatment
Common side effects
- Palpitations
- Nervousness
- Tremors
- Dizziness
- Headache
- Nausea
- Vomiting
- Diarrhea
- Abdominal pain
- Muscle weakness
Key clinical trials
- A Study of a Virtual Education-Based Transition Intervention to Improve Transition Readiness in Adolescent and Young Adults With Congenital Adrenal Hyperplasia (NA)
- Intramyocardial Injection of Autologous Umbilical Cord Blood Derived Mononuclear Cells During Surgical Repair of Hypoplastic Left Heart Syndrome (PHASE2)
- Self-Reported Pain in Children Submitted to Single Infiltration of Articaine During Primary Molar Extraction (PHASE4)
- The Incidence of Postoperative Pain After Using Different Types of Sealers (NA)
- Coring Out Fistulectomy With Closure of Internal Sphincter Opening Versus Lay Open Fistulotomy and Primary Sphincter Repair in Transsphincteric Perianal Fistula (NA)
- Feasibility of a Home Exercise Program With the Addition of a Corticosteroid Injection in Patients With Lateral Hip Pain (NA)
- Comparison of Articaine Mandibular Infiltration to Lidocaine Inferior Alveolar Nerve Block in Pediatric Patients (NA)
- A Study of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroids in Japanese Participants With Moderate-to-Severe Atopic Dermatitis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Self-injectable epinephrine CI brief — competitive landscape report
- Self-injectable epinephrine updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI